US Edition
Published • loading... • Updated
Lipocine completes Phase 3 trial of LPCN 1154 in PPD - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Lipocine completes Phase 3 trial of LPCN 1154 in PPD - BioTuesdays
Lipocine (NASDAQ: LPCN) has announced that the last patient has completed the final study visit in the Phase 3 trial of its oral brexanolon, LPCN 1154, for the treatment of postpartum depression (PPD). According to Lipocine, LPCN 1154 has shown a positive safety profile, with all reported nervous system adverse events being mild to moderate in severity, and no instances of drug discontinuation, excessive sedation, loss of consciousness, or drug-…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
